Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for AMRN
-0.110 (-10.48%)
After Hours: 0.950 +0.010 (1.06%)
Oct 24, 6:32PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.94 - 1.05
52 week 0.94 - 2.75
Open 1.02
Vol / Avg. 5.21M/2.57M
Mkt cap 182.84M
P/E     -
Div/yield     -
EPS -0.45
Shares 174.13M
Beta 0.92
Inst. own 37%
Nov 3, 2014
Q3 2014 Amarin Corporation PLC Earnings Release (Estimated) Add to calendar
Sep 16, 2014
Amarin Corporation PLC Conference Call to discuss its commitment to the REDUCE-IT study
Sep 10, 2014
Amarin Corporation PLC at Rodman & Renshaw Global Investment Conference
Aug 7, 2014
Q2 2014 Amarin Corporation PLC Earnings Call and to provide an Operational Update
Aug 7, 2014
Q2 2014 Amarin Corporation PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 121.55% -630.82%
Operating margin 101.49% -691.08%
EBITD margin - -678.95%
Return on average assets 28.85% -59.02%
Return on average equity - -
Employees 185 -
CDP Score - -


2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company�s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial).

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 53
Bio & Compensation  - Reuters
Michael J. Farrell Principal Financial Officer and Principal Accounting Officer
Age: 36
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 51
Bio & Compensation  - Reuters
David M. Stack Independent Director
Age: 62
Bio & Compensation  - Reuters
James I. Healy M.D, Ph.D. Non-Executive Independent Director
Bio & Compensation  - Reuters
Patrick J. O'Sullivan Non-Executive Independent Director
Age: 72
Bio & Compensation  - Reuters